Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Tadmor

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Leukemia|July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Blood Cancer Journal|December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaFarhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Blood|August 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLLOthman Al-Sawaf, Moritz Fürstenau, Adam Giza, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2016
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trialsMassimo Gentile, Katja Zirlik, Stefania Ciolli, et al.
Leukemia|July 22, 2018
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Leukemia|May 5, 2021
Hairy cell leukemia and COVID-19 adaptation of treatment guidelinesMichael Grever, Leslie Andritsos, Versha Banerji, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Blood|December 2, 2016
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemiaMichael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
Blood Cancer Journal|December 12, 2022
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemiaFarhad Ravandi, Robert J Kreitman, Enrico Tiacci, et al.
Pageof 15